TXG Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
151.0M
+0.1%
150.8M
-9.1%
166.0M
+11.4%
149.0M
-13.8%
172.9M
Cost of Revenue
38.5M
-13.7%
44.7M
-15.7%
53.0M
+8.8%
48.7M
+1.8%
47.8M
Gross Profit
112.5M
+6.0%
106.2M
-6.1%
113.0M
+12.7%
100.3M
-19.8%
125.1M
Operating Expenses
132.1M
+7.2%
123.2M
-7.1%
132.6M
+0.0%
132.5M
+39.6%
95.0M
R&D
56.8M
-0.1%
56.8M
+1.6%
56.0M
-2.1%
57.2M
-6.6%
61.2M
SG&A
78.7M
+18.5%
66.4M
-13.4%
76.6M
+1.7%
75.4M
+1.2%
74.4M
Operating Income
-19555000
-14.7%
-17046000
+12.8%
-19541000
+39.4%
-32242000
-207.0%
30.1M
EBITDA
-13291000
-87.5%
-7089000
+25.2%
-9476000
+56.8%
-21945000
-695.4%
-2759000
Net Income
-17931000
-33.1%
-13470000
+17.1%
-16252000
+40.8%
-27472000
-179.5%
34.5M
EPS (Basic)
$-0.14
-40.0%
$-0.10
+23.1%
$-0.13
+40.9%
$-0.22
-178.6%
$0.28
EPS (Diluted)
$-0.14
-40.0%
$-0.10
+23.1%
$-0.13
+40.9%
$-0.22
-178.6%
$0.28
Shares (Diluted)
130.0M
+1.3%
128.3M
+1.5%
126.4M
+0.7%
125.5M
+0.8%
124.5M
10x Genomics (TXG) โ€” Financials